Aesthetic use of BoNT: Options and outcomes

Gendler, Ellen C.; Nagler, Arielle R.

doi:10.1016/j.toxicon.2015.08.023

Cited by 15 publications

(21 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 However, injection of any BoNT-A into the frontalis muscles (forehead) may worsen brow ptosis, and injecting the lower part of the forehead should be avoided for this reason. 8 , 10 , 24 This is particularly the case for patients who depend on their lateral frontalis to elevate their brows in an effort to avoid accentuating dermatochalasis.…”

Section: Resultsmentioning

confidence: 99%

Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review

Cohen

Scuderi

2017

Aesthetic Surgery Journal

View full text Add to dashboard Cite

A systematic review of the published literature (from January 2000 to January 2016) to ascertain the safety of, and patient satisfaction with, the aesthetic use of abobotulinumtoxinA was conducted. In addition to the licensed indications, other special populations were considered for discussion. The potential impact of neutralizing antibodies and systemic toxicity were also addressed. A total of 364 papers were screened and 86 were found to be relevant to the population, intervention(s), and outcomes stipulated in the protocol. The safety and patient satisfaction data from these publications are discussed in this review.Level of Evidence: 2

show abstract

Section: Resultsmentioning

confidence: 99%

Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review

Cohen

Scuderi

2017

Aesthetic Surgery Journal

View full text Add to dashboard Cite

show abstract

“…The serendipitous observation that BoNT/A1 smoothed facial lines when used therapeutically (Carruthers and Carruthers, 1992) led to study the toxin effect on glabellar lines, which are perceived as a sign of aging and of negative emotions. The repetitive contraction and activity of the procerus and the corrugator supercilii muscles involved in facial expression is mainly responsible for glabellar lines and can be attenuated by BoNT/A1 injection into three to five sites of these muscles (Gendler and Nagler, 2015). A recent meta-analysis showed that a 20 U total dose of BoNT/A1 is remarkably effective and safe for the treatment of glabellar lines (Guo et al., 2015).…”

Section: Pharmacologymentioning

confidence: 99%

Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology

et al. 2017

View full text Add to dashboard Cite

The study of botulinum neurotoxins (BoNT) is rapidly progressing in many aspects. Novel BoNTs are being discovered owing to next generation sequencing, but their biologic and pharmacological properties remain largely unknown. The molecular structure of the large protein complexes that the toxin forms with accessory proteins, which are included in some BoNT type A1 and B1 pharmacological preparations, have been determined. By far the largest effort has been dedicated to the testing and validation of BoNTs as therapeutic agents in an ever increasing number of applications, including pain therapy. BoNT type A1 has been also exploited in a variety of cosmetic treatments, alone or in combination with other agents, and this specific market has reached the size of the one dedicated to the treatment of medical syndromes. The pharmacological properties and mode of action of BoNTs have shed light on general principles of neuronal transport and protein-protein interactions and are stimulating basic science studies. Moreover, the wide array of BoNTs discovered and to be discovered and the production of recombinant BoNTs endowed with specific properties suggest novel uses in therapeutics with increasing disease/symptom specifity. These recent developments are reviewed here to provide an updated picture of the biologic mechanism of action of BoNTs, of their increasing use in pharmacology and in cosmetics, and of their toxicology.

show abstract

“…4,34,36 Most authors attributed these side effects to abnormal BoNT diffusion and subsequent paralysis of surrounding muscles. 47,48 A cadaver study found that the risorius muscle attaches to the anterior or middle part of the masseter in more than 95% of individuals, making it especially prone to collateral toxin effect. 49 To minimize the incidence of nonmasseteric muscular paralysis, the physician should be familiar with muscular anatomy, set an injection safe zone at least 1 cm from the anterior border of the masseter, and keep to a deep injection level.…”

Section: Changes In Facial Expressionmentioning

confidence: 99%

Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy

Yeh¹,

Peng²,

Peng³

2018

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Botulinum toxin masseter injections are commonly performed procedures with good results and safety profiles. The majority of complications appeared within 2-4 weeks of injection and disappeared within 12 weeks. Despite the temporary nature of these complications, they often decrease patient satisfaction and confidence, so physicians should familiarize themselves with the regional anatomy and injection safety zones.

show abstract

Aesthetic use of BoNT: Options and outcomes

Cited by 15 publications

References 51 publications

Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review

Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review

Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology

Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy

Contact Info

Product

Resources

About